Research Projects

TLS is involved in an increasing number of research projects aimed at responding to major health challenges such as bacterial resistance to antibiotics or orphan diseases, as well as at investigating the mechanisms of progression and regression of leukemia and blood cancers or the effectiveness of the application of vaccines to immuno-oncology.
The Foundation is currently the host institution of important research projects, three of which are funded by the European Research Council (ERC), one by the Wellcome Trust, one by the Wellcome Leap and one made possible thanks to funding from AIRC (Italian Association for Cancer Research).
In particular, following the spread of the SARS-CoV-2 coronavirus, in March 2020 TLS promptly started the MAbCo19 project for the development of a cure for COVID-19, relying on the expertise of the MAD Lab and on important sources of funding.
TLS has also consolidated its third-party research and development activities, for which it is involved in important projects mainly related to the use of skills and expertise in proteomics.


Preparations based on medicinal plants or “botanicals” represent an important segment of the Italian and European health market. Their long tradition of use represents a guarantee of safety and efficacy.


The DaScH-Lab can rely on the expertise of a diverse group of computational and machine-learning scientists working at the interface with experimental teams on a wide range of life science challenges.


The project aims at investigating the role of gut microbiome in determining the efficacy of cancer vaccines. The research project, awarded to Prof. Guido Grandi, University of Trento, has a term of five years and benefits from 2.5 million euros of funding. TLS hosts some labs and scientists.

Hyper Antibody Research Development (HARD) LAB

The High-Throughput Antibody Research and Development Lab (HARD-Lab) is dedicated to cutting-edge research and development in the field of antibody-based diagnostics and therapeutics, focusing on areas of medical importance such as oncology, metabolic, infectious, and rare diseases.


IDF SHARID focuses on the application of key technologies in the bioinformatics, biomedical and biotechnological fields, and their subsectors, through which it aims at developing innovative therapy instruments.


The Mass Spectrometry Unit (MSU) is a well-established reality within TLS consisting of a multidisciplinary team which, by combining mass spectrometry with bioinformatic data processing, deals with the cross-sectional analysis of a wide variety of samples to investigate their protein and metabolic profile.


The MAD Lab research team at the Fondazione TLS started its activities in 2018 thanks to a 2.5-million-euro ERC Advanced Grant focused on anti-microbial resistance.


The TLS Foundation has explicitly identified work in the field of orphan diseases among its institutional objectives, looking, in particular, to act as a link between basic research and industrial application in the biomedical and pharmaceutical fields.


The TUMor Immunology (TUMI) unit led by Dr. Anna Kabanova was established with the support of the program called “My First AIRC grant” of the Italian Association for Cancer Research. “My First AIRC” aims to support young researchers in establishing independent laboratories to pursue cancer-related research.

Join the TLS mailing list Subscribe

TLS Research

visit the other sections

Scientific Publications

In recent years, the increasing commitment of TLS to in-house research has produced a significant growth of the scientific contribution of the foundation’s researchers